MDCX (medicuspharma.com) Market Value to Book Value Ratio

Official company branding of Medicus Pharma Ltd (MDCX)

The asset value of Medicus Pharma Ltd. (MDCX), currently -2.42 as shown on the chart, demonstrates the business's resilience to global crises due to the specific nature of medical cycles. Medicus Pharma Ltd. (MDCX) develops innovative patches to combat skin oncology, leveraging unique patents to protect against price wars. The company's success relies on clinical trial results and regulatory approvals in its competition with traditional surgery.

MDCX Medicus Pharma Corp: Market Value to Book Value in the range 11/15/2024 - 10/28/2026

Financial and market metric breakdowns for Medicus Pharma Ltd (MDCX)

- price and consensus price forecast:
Stock Quotes Medicus Pharma Ltd.|MDCX - Broker Consensus Forecast
- market capitalization data:
Market Value Medicus Pharma Limited|MDCX - Full Business Value
- book capitalization data:
Book Value per Share Medicus Pharma|MDCX - Accounting Value of Company|Market Capitalization to Book Value Ratio medicuspharma.com|MDCX - Company Total Assets
- debt and liquidity data:
Debt to Equity Medicus Pharma Ltd.|MDCX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Medicus Pharma Limited|MDCX - Company Total Debt|Debts to Book Capitalization Medicus Pharma Limited|MDCX - Company Long-Term Debts|Company Current Liabilities Medicus Pharma
Initial company analysis:Medicus Pharma Ltd. - MDCX
Original product of Medicus Pharma Limited

Investors are assessing the stability of Medicus Pharma Ltd. (MDCX) through the lens of its reliance on external financing for clinical development. The absence of operational cash flow renders the company's assets a pledge for its future. This metric compares the business's market value with its net book assets to determine the expectation premium. By analyzing the change in the market cap to book capitalization ratio on GURU.Markets, one can evaluate the efficiency of capital management. This trend serves as an indicator of market confidence in the commercialization of the company's drugs.

Main competitors

Market Cap to Net Assets Ratio Krystal Biotech, Inc.|APGE (apogeetherapeutics.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Arcutis Biotherapeutics, Inc. ARQT|Market Capitalization to Net Assets Vericel Corp|Oruka Corp (ORKA) - Market Capitalization to Book Value Ratio|Market Value to Book Value sanaramedtech.com (SMTI)|Market Capitalization to Book Value Ratio DBVT (DBV Technologies)|Solesence Beauty - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Journey Medical Corp. (DERM)|FBRX: Market Value to Book Value|EMPG (Empro) - Market Value to Book Value Ratio|Sol-Gel Technologies, Ltd. (SLGL) - Market Cap to Net Assets Ratio|AXIL (AXIL Brands Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Verrica (VRCA)|Hoth Therapeutics, Inc. (HOTH) - Market Cap to Net Assets Ratio|Market Value to Book Value BFRI (biofrontera-us.com)|Market Value to Book Value Ratio VYNE|Sonoma Pharmaceuticals Inc. - Market Capitalization to Book Value|Quoin Pharma - Market Value to Book Value Ratio|AZTR - Market Capitalization to Book Value Ratio|Dermata Therapeutics, Inc. - Market Capitalization to Book Value Ratio|ELAB (Elevai Labs Inc) - Market Capitalization to Book Value|Market Value to Book Value Ratio Revance Therapeutics, Inc (RVNC)